October 2021 Price Concessions 2nd Update
THIS CONTENT HAS NOW EXPIRED
The Department of Health and Social Care (DHSC) has today granted the following list of price concessions:
Drug | Pack size | Price Concession |
Clomipramine 50mg capsules | 28 | £8.60 |
Glyceryl trinitrate 400micrograms/dose pump sublingual spray | 180 | £2.83 |
Hypromellose 0.5% eye drops | 10 | £1.17 |
Lercanidipine 10mg tablets | 28 | £2.99 |
Lercanidipine 20mg tablets | 28 | £2.96 |
Loratadine 5mg/5ml oral solution | 100 | £6.92 |
Orlistat 120mg capsules | 84 | £25.50 |
Perindopril erbumine 8mg tablets | 30 | £2.14 |
Tolbutamide 500mg tablets | 28 | £26.00 |
The DHSC previously announced (15.10.2021) the following list of price concessions:
Drug | Pack size | Price Concession |
Glyceryl trinitrate 400micrograms/dose pump sublingual spray | 200 | £2.83 |
Lamotrigine 5mg dispersible tablets sugar free | 28 | £8.43 |
Methocarbamol 750mg tablets | 100 | £12.37 |
Pioglitazone 45mg tablets | 28 | £2.40 |
Timolol 0.25% eye drops | 5 | £4.16 |
Timolol 0.5% eye drops | 5 | £4.10 |
Trimethoprim 50mg/5ml oral suspension sugar free | 100 | £10.99 |
Ursodeoxycholic acid 250mg capsules | 60 | £10.53 |
No additional endorsements are required for price concessions. A price concession only applies for the month in which it is granted.
PSNC is still working with the DHSC to agree further concessionary prices on other drugs reported to be unavailable at the stated October 2021 Drug Tariff price. Please note that PSNC cannot provide details of any generic products awaiting price concession approval from DHSC.
If you have problems obtaining a Part VIII product at the stated Drug Tariff price, please report the issue using the online feedback form on the PSNC website. Please include full details of the supplier and price paid for any products sourced above the Drug Tariff price. PSNC will investigate the extent of the problem and, if appropriate, discuss the issue with DHSC.
Contractors will be alerted to further updates to the price concession list through our website and via our e-news email. If you wish to subscribe to our email list, you can receive an email as soon as any announcements are made.